Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | CPA1 | P15085 | 2/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634343 | 1.00 | PTPN1 (0.43) | PTPN1CTSSCTSKACEDPP4 | |
| SCHEMBL1509374 | 0.88 | PTPN1 (0.53) | PTPN1CTSSCTSKACEDPP4 | |
| SCHEMBL1509372 | 0.88 | PTPN1 (0.53) | PTPN1CTSSCTSKACEDPP4 | |
| SCHEMBL30599288 | 0.88 | PTPN1 (0.53) | PTPN1CTSSCTSKACEDPP4 | |
| SCHEMBL18124300 | 0.88 | PTPN1 (0.53) | PTPN1CTSSCTSKACEDPP4 | |
| SCHEMBL29398092 | 0.88 | PTPN1 (0.53) | PTPN1CTSSCTSKACEDPP4 | |
| SCHEMBL29162457 | 0.80 | PTPN1 (0.50) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL1509413 | 0.79 | PTPN1 (0.49) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL1509411 | 0.79 | PTPN1 (0.49) | PTPN1CTSSCTSKACESCN9A | |
| SCHEMBL16448118 | 0.78 | PTPN1 (0.48) | PTPN1CTSSCTSKACESCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259160-B2 | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20060211682-A1 | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211682-A1 | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PTPN1 1435/4885CTSS 933/4885CTSK 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.